000 | 01920 a2200517 4500 | ||
---|---|---|---|
005 | 20250514010145.0 | ||
264 | 0 | _c20011018 | |
008 | 200110s 0 0 eng d | ||
022 | _a1078-8956 | ||
024 | 7 |
_a10.1038/nm0901-1041 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aDormond, O | |
245 | 0 | 0 |
_aNSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. _h[electronic resource] |
260 |
_bNature medicine _cSep 2001 |
||
300 |
_a1041-7 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology |
650 | 0 | 4 |
_aCell Division _xdrug effects |
650 | 0 | 4 |
_aCell Movement _xdrug effects |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 | _aCyclooxygenase 2 |
650 | 0 | 4 | _aCyclooxygenase 2 Inhibitors |
650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xpharmacology |
650 | 0 | 4 |
_aDinoprostone _xpharmacology |
650 | 0 | 4 |
_aEndothelium, Vascular _xcytology |
650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xpharmacology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIsoenzymes _xantagonists & inhibitors |
650 | 0 | 4 | _aMembrane Proteins |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Nude |
650 | 0 | 4 |
_aNeovascularization, Physiologic _xdrug effects |
650 | 0 | 4 |
_aNitrobenzenes _xpharmacology |
650 | 0 | 4 | _aProstaglandin-Endoperoxide Synthases |
650 | 0 | 4 |
_aReceptors, Vitronectin _xantagonists & inhibitors |
650 | 0 | 4 |
_aSulfonamides _xpharmacology |
650 | 0 | 4 |
_aThromboxane A2 _xpharmacology |
650 | 0 | 4 |
_acdc42 GTP-Binding Protein _xdrug effects |
650 | 0 | 4 |
_arac GTP-Binding Proteins _xdrug effects |
700 | 1 | _aFoletti, A | |
700 | 1 | _aParoz, C | |
700 | 1 | _aRüegg, C | |
773 | 0 |
_tNature medicine _gvol. 7 _gno. 9 _gp. 1041-7 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1038/nm0901-1041 _zAvailable from publisher's website |
999 |
_c11457491 _d11457491 |